Interim Report 2014 - full report In the first

News Desk 2018 · 2014-08-14T02:30:12-04:00

Interim Report 2014 - full report In the first half-year, the Group realised a growth rate of 8% in local currencies, corresponding to revenue of DKK 4,539 million. The Group’s core business, wholesale of hearing aids, realised unit growth, clearly exceeding unit growth in the market. A continued roll-out of new products is planned for the third quarter. The period under review was characterised by a high level of spending and investments in relation to the establishment of a new distribution centre, the transfer of ITE production to Poland, the roll-out of global IT projects and the expansion of Oticon Medical, all of which will secure future growth and profitability for the Group. In the first half-year, Oticon Medical continued to deliver double-digit sales growth, both in bone-anchored hearing systems (BAHS) and in cochlear implants (CI). The feedback provided on our CI products at the recently held CI conference in Munich was very encouraging – strongly supported by an independent study, demonstrating in three out of four tests the superior performance of our Saphyr Neo speech processor compared to speech processors from our competitors. In addition to the adverse effects of current spending on operating profit (EBIT) in the first half-year, foreign exchange rates negatively impacted EBIT by DKK 60-70 million. EBIT reached DKK 834 million, and the EBIT margin was realised at 18.4%. Earnings per share (EPS) were realised at DKK 11.2, matching last year’s level. The expected continued strong cash flow generation combined with a limited pipeline of acquisition opportunities leaves room for channelling the Group’s substantial excess cash flow back to the shareholders going forward. Therefore, we plan to buy back Company shares worth a total of DKK 2.5-3.0 billion in the period 2014-2016 of which amount we have year-to-date already bought back shares worth DKK 493 million. We maintain our full-year outlook for 2014, including our expectation to generate growth in both our business activities and to deliver a rise in earnings per share of 5-10%. Acquisitions are expected to contribute by 3-4% to Group revenue in 2014, even though we expect more than half of this impact to be offset by the Group’s weakened invoicing currencies.

New Post Public Reply Private Reply Replies (0) Message Board

Newer Older

News Desk 2018

Aug 14, 2014 at 2:30 AM

Interim Report 2014 - full report

In the first half-year, the Group realised a growth rate of 8% in local currencies, corresponding to revenue of DKK 4,539 million. The Group’s core business, wholesale of hearing aids, realised unit growth, clearly exceeding unit growth in the market. A continued roll-out of new products is planned for the third quarter.
The period under review was characterised by a high level of spending and investments in relation to the establishment of a new distribution centre, the transfer of ITE production to Poland, the roll-out of global IT projects and the expansion of Oticon Medical, all of which will secure future growth and profitability for the Group.
In the first half-year, Oticon Medical continued to deliver double-digit sales growth, both in bone-anchored hearing systems (BAHS) and in cochlear implants (CI). The feedback provided on our CI products at the recently held CI conference in Munich was very encouraging – strongly supported by an independent study, demonstrating in three out of four tests the superior performance of our Saphyr Neo speech processor compared to speech processors from our competitors.
In addition to the adverse effects of current spending on operating profit (EBIT) in the first half-year, foreign exchange rates negatively impacted EBIT by DKK 60-70 million. EBIT reached DKK 834 million, and the EBIT margin was realised at 18.4%. Earnings per share (EPS) were realised at DKK 11.2, matching last year’s level.
The expected continued strong cash flow generation combined with a limited pipeline of acquisition opportunities leaves room for channelling the Group’s substantial excess cash flow back to the shareholders going forward. Therefore, we plan to buy back Company shares worth a total of DKK 2.5-3.0 billion in the period 2014-2016 of which amount we have year-to-date already bought back shares worth DKK 493 million.
We maintain our full-year outlook for 2014, including our expectation to generate growth in both our business activities and to deliver a rise in earnings per share of 5-10%. Acquisitions are expected to contribute by 3-4% to Group revenue in 2014, even though we expect more than half of this impact to be offset by the Group’s weakened invoicing currencies.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Rise Treatment Center Launches in Vegas for Teens

Las Vegas Debuts Rise Adolescent Treatment Center Imagine being a parent in Las Vegas, staring at the daunting task of finding genuine help for your teenage kid just entering those rebellious years. The choices usually feel sparse and lacking. But on August 13, 2026, a shimmer of hope illuminated the landscape with the opening of Rise Adolescent Treatment Center. It’s a...

Unicycive's Legal Turmoil: Opportunity for Investor Action

Unicycive's Legal Headache: What's Brewing? Here we go again, folks. If you're holding shares of Unicycive Therapeutics, Inc. (UNCY), buckle up because it's looking like a storm's on the horizon. The Law Offices of Howard G. Smith have dropped the news that shareholders can step up to lead a securities fraud class action lawsuit against the company. That chance to be part...

Brands Must Choose: Cost or Value Leadership?

Navigating the Business Jungle: Strategic Choices Unveiled If you've ever found yourself tangled in a web of corporate doublespeak, then you'll nod along with this: all those lofty brand management strategies often boil down to a fight over dollars or dizzying customer satisfaction. What's the winning play? According to Info-Tech Research Group, it's about firmly standing...

CATL Opens Europe's Largest Battery Service Hub

A New Era for EV Batteries in Norway Stepping into Oslo's tech realm, CATL's grand opening is not just another corporate ribbon-cutting spree. It's a big splash in Europe's battery pool, boasting the largest NING SERVICE center outside of Asia. Here we are, folks, at the crossroads where the EV market meets the nitty-gritty of practical service. Norway's Electric...

Lincoln Educational Services Faces Securities Fraud Suit

A Storm Brews Over Lincoln Educational Services You know, there's nothing quite like the stink of a good mess in the markets, and Lincoln Educational Services Corporation has found itself knee-deep in one. The buzz is all about some securities fraud allegations that could rope in a bunch of investors who got the short end of the stick. It’s lawsuits like these that make...

NORD Honors Innovators Shaping Rare Disease Treatment

Saluting the Trailblazers in Rare Disease Space Alright, let's cut to it. In a world flooded with more rare diseases than most of us can count, about 10,000 of them, only a measly 5% have any kind of approved treatment. The National Organization for Rare Disorders (NORD) is out here celebrating the folks who dare to change that bleak outlook. With the 2026 Rare Impact...

Starr Conspiracy Unveils AI Tool for B2B Tech Firms

AI-Driven Insight in Minutes: A Game Changer for B2B Hold onto your hats, because The Starr Conspiracy just lit a fire in the B2B tech world with its latest offering—Battle Card Builder. This free tool cranks out competitive intelligence in no time, literally about four minutes. Geared specifically for B2B tech marketing and sales teams, it combines decades of know-how...

Subaru, Motorq Offer Hardware-Free Fleet Telematics Insights

An Unplugged Move in Fleet Management There's something brewing between Motorq and Subaru that could shake up fleet operations in ways most haven't thought possible yet. We’re talking about cutting those pesky hardware cords and diving straight into a future that's software-driven—and hey, we're all here for it. Direct, Data-Driven Leadership Imagine you're a fleet...

illycaffè's B Corp™ Recertification Reflects Bold Commitment

illycaffè Hits Milestone with B Corp™ Recertification In an era where corporate responsibility isn't just fodder for feel-good presentations, illycaffè has proven it’s not just paying lip service to the idea. The Italian coffee titan has secured its B Corp™ recertification under snazzier, sharper V2 standards. This isn't just a shiny sticker to slap on marketing...

Microplastics Webinar: Navigating Complex Regulations

Buckle up, folks. The plastics debate is where regulatory battles and environmental concerns collide, and big changes are on the horizon. Let's talk about Bergeson & Campbell's latest shindig: "Plastics and Policy: Microplastics, EPR, and Other Emerging Trends"—a free-to-join webinar aiming to lift the lid on what's brewing beneath the surface of regulatory waters. The...